Patents by Inventor Josephine Dunne

Josephine Dunne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF HMG-COA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT
    Publication number: 20120164221
    Abstract: The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy, or rhabdomyolysis.
    Type: Application
    Filed: October 27, 2011
    Publication date: June 28, 2012
    Inventors: David J. Bova, Josephine Dunne
  • (MONITORING ONLY) COMBINATIONS OF HMG-COA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPELIPIDEMIA ONCE A DAY AT NIGHT
    Publication number: 20090226518
    Abstract: The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis.
    Type: Application
    Filed: February 27, 2009
    Publication date: September 10, 2009
    Inventors: David J. Bova, Josephine Dunne
  • Combinations of HMG-COA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
    Publication number: 20050255158
    Abstract: The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis.
    Type: Application
    Filed: January 5, 2005
    Publication date: November 17, 2005
    Inventors: David Bova, Josephine Dunne
  • Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hypelipidemia once a day at night
    Publication number: 20040053975
    Abstract: The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis.
    Type: Application
    Filed: September 2, 2003
    Publication date: March 18, 2004
    Inventors: David J. Bova, Josephine Dunne
  • Controlled release pharmaceutical composition
    Publication number: 20030165562
    Abstract: A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicament, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.
    Type: Application
    Filed: January 6, 2003
    Publication date: September 4, 2003
    Inventors: Jose Gutierrez-Rocca, Josephine Dunne, Saul A. Rios
  • Controlled release pharmaceutical composition
    Patent number: 6596308
    Abstract: A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicant, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: July 22, 2003
    Assignee: Kos Pharmaceuticals, Incorporated
    Inventors: Jose Gutierrez-Rocca, Josephine Dunne, Saul A. Rios
  • Controlled release pharmaceutical composition
    Publication number: 20030118639
    Abstract: A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicament, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.
    Type: Application
    Filed: August 5, 2002
    Publication date: June 26, 2003
    Inventors: Jose Gutierrez-Rocca, Josephine Dunne, Saul A. Rios
  • Controlled release pharmaceutical composition
    Patent number: 6524615
    Abstract: A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicament, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: February 25, 2003
    Assignee: Kos Pharmaceuticals, Incorporated
    Inventors: Jose Gutierrez-Rocca, Josephine Dunne, Saul A. Rios
  • Release pharmaceutical construct for gastric retention
    Publication number: 20030008007
    Abstract: A pharmaceutical construct is disclosed. The construct comprises at least a first region comprising a first superporous hydrogel having a selected medicament associated therewith to form an associated region. A second region of the construct comprising a second superporous hydrogel is attached to at least a portion of the associated region to seal the medicament therebetween.
    Type: Application
    Filed: April 19, 2002
    Publication date: January 9, 2003
    Inventors: Jose Gutierrez-Rocca, Josephine Dunne, Mathew Lally
  • Controlled release pharmaceutical composition
    Patent number: 6491950
    Abstract: A controlled release pharmaceutical formulation is disclosed. The formulation comprises a construct having a matrix of a material selected from the group comprising (a) a high melting point fatty acid ester, (b) an oil, (c) a polymeric cellulose derivative and (d) a mixture of any of the foregoing. Associated with the matrix is a selected medicament. Preferably, the matrix comprises at least two of the aforementioned materials or components.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: December 10, 2002
    Assignee: Kos Pharmaceuticals, Inc.
    Inventors: Jose Gutierrez-Rocca, Josephine Dunne
  • Controlled release pharmaceutical composition
    Publication number: 20020160041
    Abstract: A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicament, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.
    Type: Application
    Filed: February 21, 2001
    Publication date: October 31, 2002
    Inventors: Jose Gutierrez-Rocca, Josephine Dunne, Saul A. Rios
  • COMBINATIONS OF HMG-COA REDUCTASE INHIBITORS AND NICOTINIC ACID AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT
    Publication number: 20010006644
    Abstract: The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy or rhabdomyolysis.
    Type: Application
    Filed: July 31, 1997
    Publication date: July 5, 2001
    Inventors: DAVID J. BOVA, JOSEPHINE DUNNE